Q2 FY2026 EarningsQ2 FY26 results significantly exceeded expectations on both the top and bottom lines, with revenue reaching $2,736M (+3% YoY) vs. $2,461M consensus. Non-GAAP diluted EPS of $3.60 beat the $2.03 estimate by 77.4%, driven by a 24% YoY surge in the "Growth Portfolio" which now offsets legacy MS declines. Following the strategic Apellis acquisition, Biogen raised its FY26 underlying EPS guidance by $0.60 to $15.85-$16.85, although reported guidance was adjusted downward to $12.00-$13.00 to account for transaction dilution and IPR&D charges.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Biogen(BIIB) the Revenue is 2.736 B (+3.42%), Beat estimate;the EBIT is 885.9 M (-15.14%), Beat estimate;the EPS is 0.66 (-84.76%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
2.74B3.42%
2.46B6.99%
+0.28B10.41%
EBITExceed expectations
0.89B15.14%
0.60B42.25%
+0.28B27.11%
EPSExceed expectations
0.6684.76%
-1.0052123.21%
+1.665238.45%
Upcoming earnings report - Q3 FY2026
Available dateOct 28, 2026
Estimate Revenue$2.635 B
Estimate EBIT$461.04 M
Estimate EPS$0.653
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf